Company profile: PMV Pharma
1.1 - Company Overview
Company description
- Provider of p53-targeted small molecule therapeutics for cancer, including the investigational candidate rezatapopt (PC14586) designed to reactivate the p53 Y220C mutation for advanced solid tumors. Offers drug discovery focused on restoring mutant p53 tumor suppressor function and conducts clinical trials to assess safety and efficacy in patients with specific p53 mutations.
Products and services
- Clinical Trials: Executes mutation-guided research studies assessing safety and efficacy of rezatapopt and other investigational p53-targeted products in patients with specific p53 mutations and advanced solid tumors
- Drug Discovery: Develops mutation-specific small molecule therapeutics that target mutant p53 and restore its tumor suppressor function for cancer treatment, creating investigational products for patients with specific p53 mutations
- Rezatapopt (PC14586): Investigational small-molecule product engineered to reactivate the p53 Y220C mutation and restore tumor suppressor function, currently in clinical trials treating advanced solid tumors with specific p53 mutations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PMV Pharma
Trethera
HQ: United States
Website
- Description: Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trethera company profile →
Living Pharma
HQ: United States
Website
- Description: Provider of Personalized CAR T Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Living Pharma company profile →
Anaveon
HQ: Switzerland
Website
- Description: Provider of IL-2-based immunotherapies developing selective IL-2 complexes that promote effector T cell functions as immune adjuvants for cancer, with candidates including ANV419, an IL-2 agonist that favors effector over regulatory T cells and shows clinical efficacy, and ANV600, a bispecific targeting IL-2 to tumor-specific cells, with Phase 1/2 planned for Q2/2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaveon company profile →
Ikena Oncology
HQ: United States
Website
- Description: Provider of novel biomarker-driven targeted cancer therapies, advancing a pipeline focused on the Hippo and RAS signaling pathways to address cancer growth, spread, and resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikena Oncology company profile →
Alpha-9 Theranostics
HQ: Canada
Website
- Description: Provider of radiotherapeutics for solid and hematologic malignancies, developing peptide-based radiopharmaceuticals that combine binders, linkers, chelators, and radioisotopes for selective radiation delivery. Services include target selection, imaging and dosimetry studies, therapy studies, and R&D supported by Vancouver research facilities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpha-9 Theranostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PMV Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PMV Pharma
2.2 - Growth funds investing in similar companies to PMV Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PMV Pharma
4.2 - Public trading comparable groups for PMV Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →